Study of Serum Fibroblast Growth Factor 23 as a Predictor of Endothelial Dysfunction among Egyptian Patients with Diabetic Kidney Disease

Bibliographic Information
Authors: Fayed A.; Mohamed A.; Ahmed R.M.; Abouzeid S.; Soliman A.
Journal: Saudi Journal of Kidney Diseases and Transplantation
Publisher: Wolters Kluwer Medknow Publications
Publication Date: 12 February 2024
Volume / Issue: Volume 34 / Issue 4
Pages: 305–312
ISSN: 13192442
Scopus: View on Scopus
PubMed: 38345585
Document Type: Article
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
Fayed A., Department of Internal Medicine, Nephrology Unit, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt; Mohamed A., Department of Internal Medicine, Nephrology Unit, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt; Ahmed R.M., Department of Internal Medicine, Nephrology Unit, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt; Abouzeid S., Department of Nephrology, Theodor Bilharz Research Institute, Cairo, Egypt; Soliman A., Department of Internal Medicine, Nephrology Unit, Kasr Alainy School of Medicine, Cairo University, Cairo, Egypt
Abstract
Endothelial dysfunction in patients with diabetic nephropathy is caused by nontraditional factors in addition to common risk factors (e.g., hypertension) in people with normal kidney function. These nontraditional factors include factors involved in mineral bone disease in these patients. One of these factors is fibroblast growth factor 23 (FGF-23). We aimed to evaluate the relationship between flow-mediated dilatation (FMD) as a measure of endothelial dysfunction and FGF-23. This was a cross-sectional observational study that was conducted on 100 diabetic patients (Group I: 50 patients with nephropathy; Group II: 50 patients without nephropathy) and 50 healthy volunteers (Group III). Serum levels of intact FGF-23, interleukin-6, intact parathyroid hormone, and 25-hydroxyvitamin D (25-(OH)Vit D); estimated insulin resistance; and FMD were evaluated. FGF-23 was significantly higher in Group I (median: 101 pg/mL) and Group II (median: 101 pg/mL) than in Group III (median: 4 pg/mL) (P <0.001), but FGF-23 was not significantly different between Groups I and II. A significant positive correlation was found between serum levels of FGF-23 and phosphorus in Group I. A significant negative correlation was found between serum levels of FGF-23 and 25-(OH)Vit D in Group II. However, FGF-23 failed to show a significant correlation with FMD in patients with diabetic nephropathy. Our data suggest another factor that rises earlier than FGF-23 in diabetic nephropathy and causes endothelial dysfunction. © 2023 Saudi Center for Organ Transplantation.
Keywords
Cross-Sectional Studies; Diabetes Mellitus; Diabetic Nephropathies; Egypt; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Vascular Diseases; fibroblast growth factor; fibroblast growth factor 23; cross-sectional study; diabetic nephropathy; human; vascular disease
Citation Information
Scopus Citations: 2
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
